Randomized controlled trialHumanClinical Trial, Phase II
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Nature communications, 2023 Dec 14. Ji L, Jiang H, Cheng Z and 18 others.
Study type
Randomized controlled trial · Clinical Trial, Phase II
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Nature communications
Published
2023 Dec 14
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultHumansOverweightHypoglycemic AgentsDiabetes Mellitus, Type 2ObesityBody WeightGlucagon-Like Peptide 1Double-Blind MethodTreatment OutcomePeptides
Other papers on Mazdutide
Systematic review / meta-analysis · 2026
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials
Randomized controlled trial · 2026Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial
Randomized controlled trial · 2025Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page